Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND AND PURPOSE: Analyses of trends in the delivery of time critical treatments typically report the median, but measures of central tendency may ignore important changes for specific patient groups. We considered whether this was an important effect during comparison of onset to treatment (OTT) time between 2 cohorts of patients with stroke receiving intravenous thrombolysis. METHODS: After controlling for stroke severity, a relative distributions technique compared OTT for UK patients treated with recombinant tissue-type plasminogen activator registered within the first and last quarters (each n=661) of the Safe Implementation of Thrombolysis in Stroke-Monitoring Study database between January 2003 and September 2010. RESULTS: Significant differences were found between OTT distributions. Overall, the second cohort's OTT distribution demonstrated simultaneous increases in the proportion of patients with faster and slower OTT, which resulted in no net effect on the median after correction for stroke severity. CONCLUSIONS: Medians did not adequately describe distributional changes. Faster OTT may be because of more efficient processes in acute stroke centers and improved symptom recognition by the public. Slower OTT is likely to reflect movement from a 3- to a 4.5-hour OTT target. Relative distributions offer new insights into historical trends and service evaluation where time critical treatments are involved.

Original publication

DOI

10.1161/STROKEAHA.115.008724

Type

Journal article

Journal

Stroke

Publication Date

05/2015

Volume

46

Pages

1381 - 1383

Keywords

thrombolysis, therapeutic, Aged, Aged, 80 and over, Cohort Studies, Data Interpretation, Statistical, Female, Fibrinolytic Agents, Humans, Male, Middle Aged, Stroke, Thrombolytic Therapy, Time-to-Treatment, Tissue Plasminogen Activator, Treatment Outcome, United Kingdom